Drug name - Lokelma

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(9 years from now)

US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(11 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(11 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(11 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(13 years from now)

US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(13 years from now)

CN103534209A ASTRAZENECA Microporous Zirconium Silicate For The Treatment Of Hyperkalemia
Mar, 2019

(3 years ago)

CN106385795A ASTRAZENECA Microporous Zirconium Silicate For Treating Hyperpotassaemia
Jul, 2019

(3 years ago)

CN104797263A ASTRAZENECA Microporous Zirconium Silicate For Treating Hyperpotassaemia
Oct, 2033

(11 years from now)

CN104797263B ASTRAZENECA For Curing Hyperpotassaemia Microporous Zirconium Silicate
Oct, 2033

(11 years from now)

CN106170283A ASTRAZENECA Micro-Pore Zirconium Silicate For Treating Hyperkalemia
Nov, 2034

(12 years from now)

CN106170283B ASTRAZENECA For Microporous Zirconium Silicate Of Curing Hyperpotassaemia
Nov, 2034

(12 years from now)

CN108137620A ASTRAZENECA Expand The Using Zirconium Silicate Composition And Use Method Thereof
Oct, 2036

(14 years from now)

CN108137620B ASTRAZENECA Method For Expanding Use Of Zirconium Silicate Composition And Method Of Using The Same
Oct, 2036

(14 years from now)

IN394538B ASTRAZENECA A Cation Exchange Composition Comprising A Zirconium Silicate
Oct, 2036

(14 years from now)

IN201817010535A ASTRAZENECA Extended Use Zirconium Silicate Compositions And Methods Of Use Thereof
Oct, 2036

(14 years from now)

EP2673237B1 ASTRAZENECA Use Of A Zirconium Silicate For The Treatment Of Hyperkalemia
Feb, 2032

(9 years from now)

EP2673237A2 ASTRAZENECA Use Of A Zirconium Silicate For The Treatment Of Hyperkalemia
Feb, 2032

(9 years from now)

EP2673237A4 ASTRAZENECA Microporous Zirconium Silicate For The Treatment Of Hyperkalemia
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia Feb, 2032

(9 years from now)

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
5GM/PACKET FOR SUSPENSION;ORAL Prescription
10GM/PACKET FOR SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.